Key facts
- BioSapien’s last known valuation is $23.0M (Jul 2025).
- It has raised $10.1M; the latest was Later Stage VC ($8.0M) in Jul 2025.
- Notable investors include US National Science Foundation, SOSV, MicroVentures, Side Door Ventures, Golden Gate Ventures — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for BioSapien
- ·The full record, as it builds
Funding rounds
No funding rounds for BioSapien are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioSapien
Developer of a three-dimensional printed drug delivery platform designed to deliver medicines in a localized, sustained manner for cancer indications. The company's platform offers products that are being designed with biodegradable mesh capable of the sustained delivery of small molecules and are affixable to delicate and complex anatomy, enabling healthcare professionals to achieve efficacy while decreasing toxicity by releasing drugs directly to a cancerous tumor site.
- Sector
- Healthcare
- HQ
- Carlsbad, CA, United States
- Founded
- 2018
- Employees
- 10
- Website
- biosapien.com/
- Ownership
- Privately Held (backing)
BioSapien doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioSapien shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioSapien in its N-PORT filings yet. We sweep new filings monthly.